A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of FT1 in Healthy Adult Volunteers
Latest Information Update: 30 Sep 2024
Price :
$35 *
At a glance
- Drugs FT 1 (Primary)
- Indications Diarrhoea
- Focus Adverse reactions; First in man
- Sponsors Chongqing Peg-Bio Biopharm
- 30 Sep 2024 New trial record